Peptide Regulation News 2026: Global Market Surges to $68.5B, Driven by GLP-1 & Novel Therapeutic Pipelines
Peptide Regulation News 2026: Global Market Surges to $68.5B, Driven by GLP-1 & Novel Therapeutic Pipelines The global peptide market is projected to reach $68.5 billion by 2026, propelled by GLP-1 receptor agonists (e.g., semaglutide) and novel therapeutic pipelines targeting oncology and metabolic disorders. Key trends include a shift toward high-purity (>99%) synthetic peptides and enhanced stability via PEGylation. Leading brands (Novo Nordisk, Eli Lilly) dominate GLP-1s, while emerging players focus on antimicrobial and anti-aging peptides. Technical advantages include high specificity and low toxicity; drawbacks include poor oral bioavailability and high manufacturing costs. Product parameters (purity, sequence length, endotoxin levels) are critical for regulatory compliance (FDA, EMA). Selection tips prioritize GMP-certified facilities, validated certificates of analysis, and cold-chain logistics (2–8°C). Industry outlook remains robust, with R&D investments rising 12% annually.